Home | Looking for something? Sign In | New here? Sign Up | Log out

Friday, January 7, 2011

GEN News Highlights - News of the Week

Friday, January 7, 2011
0 comments

Genetic Engineering & Biotechnology News
Quick Links
  Visit GEN on Twitter
 
HIGHLIGHTS OF THE WEEK
December 31, 2010 - January 6, 2011


Advertisement

SPONSORED LINK
Make your Biomanufacturing voice heard! Support effective industry growth & planning. 8th Annual Biomanufacturing study benchmarks critical global trends: Budget, new technologies, capacity, outsourcing hiring, downstream, disposables, expression systems, cost cutting, quality, more. BioPlan Associates, Inc.
FREE summary, plus donation to GAVI, or ACS
Click Here! Receive FREE summary

January 06, 2011, 10:03 AM EST
Investigators Identify Prognostic Marker for Treating Hep C with Peg-Interferon and Ribavirin
Team expects to launch a test based on the IP-10 marker this year.
January 06, 2011, 09:40 AM EST
Researchers Develop Simpler, Quicker Way of Producing AAV-Based Vectors for Gene Transfer
Method is also capable of producing high yields of multiple AAV serotypes and efficient packaging.
January 06, 2011, 10:06 AM EST
CHO Genome Sequenced by BGI and GT Life Sciences
Next step is data analysis and interpretation of genetic regulation in cell proliferation.

January 06, 2011, 10:04 AM EST
Genentech and Pfizer Join the Antibody-Drug Conjugate Bandwagon
Genentech will tap Spirogen's technology and Pfizer will use Seattle Genetics'.
January 06, 2011, 08:08 AM EST
Symphogen Raises About $134M to Progress Clinical-Stage Antibodies
Firm claims fundraising is largest ever in Europe by private biotech business.
January 05, 2011, 09:57 AM EST
Rituximab Biosimilar to Be Developed by Spectrum and Viropro
Roche/Genentech's mAb therapeutic raked in $5.6 billion in 2009 sales, and patents start expiring in 2014.
January 05, 2011, 09:09 AM EST
Merck KGaA Buys Chinese Cell Culture Media Firm Beijing Skywing for About $18.8M
It is hoped that the new client base in China will provide promising opportunities for Merck Millipore.
January 05, 2011, 08:53 AM EST
Beckman Coulter to Develop aNK Assay for Pivotal Trial of Transgene's NSCLC Drug
French company projects that Phase IIb/III study with TG4010 will start later this year.
January 04, 2011, 10:29 AM EST
Genetic Link for Depression Furthered by Analysis of 54 Studies
Results challenge an evaluation of 14 studies that contradicted the initial discovery of this association.
January 04, 2011, 09:55 AM EST
Pfizer Pays $14M to Expand RNA Partnership with Santaris Pharma
Pfizer is adding 10 more targets, which could draw $600 million in milestones.
January 03, 2011, 09:43 AM EST
Sigma-Aldrich Takes Over Cerilliant to Pad Analytical Chemistry Portfolio
Acquired firm has over 2,800 products related to reference standards and materials.


You can view more news broken down into over 90 categories and updated daily.


Analysis & Insight
Analysis & Insight 2010 in Review: Biotechnology Highlights
Gene patenting and ESCs were back in the headlines along with breakthroughs in sequencing, syn bio, and other fields.     More A&Is

Article from GEN's January 1 Issue
Is Innovation Finally Beginning to Pay Off?
The success rate in 2010 can be chalked up to the focus on cutting-edge technologies.



Webinars
Available on Demand: Original Broadcast Date - December 16, 2010
Simplifying Targeted Protein Quantification with Mass Spec: The SRM Atlas and Multiplexed MRM Protein Assays
Sponsored by: Agilent Technologies

In Case You Missed It:
If you couldn't attend a previous webinar, be sure to check out our On-Demand Archives.


Application Note Library
More App Notes



Online Exclusives

BLOGBIOTECH:
Will FDA Bid Adieu to Auld Lang Syne and Open Up to New Drugs and Devices    More Blogs


More at GEN
GEN Subscriber Tools



Subscription Center l Unsubscribe l Update Your Profile l About GEN

IMPORTANT! Make sure you receive your chosen GEN e-Newsletters. Add update@genengnews.com to your Address Book or Safe Senders List. It's easy! Click HERE for instructions.

Contact Us For:
Advertising   Editorial   Business and Partnership Opportunities


This email was sent by:
Genetic Engineering & Biotechnology News
140 Huguenot St.,
New Rochelle, NY 10801, USA
 

read more

Thursday, January 6, 2011

CHO Genome Sequenced by BGI and GT Life Sciences

Thursday, January 6, 2011
0 comments

Genetic Engineering & Biotechnology News
Quick Links
  Visit GEN on Twitter
 
GEN NEWS HIGHLIGHTS
Thursday, January 6, 2011


Advertisement

SPONSORED LINK
Make your Biomanufacturing voice heard! Support effective industry growth & planning. 8th Annual Biomanufacturing study benchmarks critical global trends: Budget, new technologies, capacity, outsourcing hiring, downstream, disposables, expression systems, cost cutting, quality, more. BioPlan Associates, Inc.
FREE summary, plus donation to GAVI, or ACS
Click Here! Receive FREE summary


CHO Genome Sequenced by BGI and GT Life Sciences
Next step is data analysis and interpretation of genetic regulation in cell proliferation.

Genentech and Pfizer Join the Antibody-Drug Conjugate Bandwagon
Genentech will tap Spirogen's technology and Pfizer will use Seattle Genetics'.

Symphogen Raises About $134M to Progress Clinical-Stage Antibodies
Firm claims fundraising is largest ever in Europe by private biotech business.


Investigators Identify Prognostic Marker for Treating Hep C with Peg-Interferon and Ribavirin
Team expects to launch a test based on the IP-10 marker this year.

Researchers Develop Simpler, Quicker Way of Producing AAV-Based Vectors for Gene Transfer
Method is also capable of producing high yields of multiple AAV serotypes and efficient packaging.

Cell Medica and Baylor's CAGT Ally to Commercialize EBV-CTL Cancer Therapy
Partners will develop commercial GMP process and hope to start Phase II/III study in 2012.

GSK Licenses Immutep's T-Cell Depleting Antibodies for Autoimmune Diseases
Firm hopes selective depletion of activated T cells will lead to longer-lasting, safer therapy.

Horizon and University of Washington Partner to Apply Gene Editing to IPSCs
$400,000 project aims to generate new X-Man cell lines and bioproduction reagents.

Receptos and Lilly Enter Agreement Focused on a GPCR Target
Receptos' technology will be used to find small molecule modulators.

Chiva Nabs Chinese Rights to Ligand's Hep B and HCC Candidates
Use of Ligand's HepDirect tech for the development of new candidates against hep B, hep C, and HCC part of deal.


You can view more news broken down into over 90 categories and updated daily.



Analysis & Insight
Analysis & Insight 2010 in Review: Biotechnology Highlights
Gene patenting and ESCs were back in the headlines along with breakthroughs in sequencing, syn bio, and other fields.     More A&Is

Webinars
Available on Demand: Original Broadcast Date - December 16, 2010
Simplifying Targeted Protein Quantification with Mass Spec: The SRM Atlas and Multiplexed MRM Protein Assays
Sponsored by: Agilent Technologies

In Case You Missed It:
If you couldn't attend a previous webinar, be sure to check out our On-Demand Archives.


Application Note Library
More App Notes

Online Exclusives

BLOGBIOTECH:
Will FDA Bid Adieu to Auld Lang Syne and Open Up to New Drugs and Devices    More Blogs


More at GEN
GEN Subscriber Tools



Subscription Center l Unsubscribe l Update Your Profile l About GEN

IMPORTANT! Make sure you receive your chosen GEN e-Newsletters. Add update@genengnews.com to your Address Book or Safe Senders List. It's easy! Click HERE for instructions.

Contact Us For:
Advertising   Editorial   Business and Partnership Opportunities


This email was sent by:
Genetic Engineering & Biotechnology News
140 Huguenot St.,
New Rochelle, NY 10801, USA
 

read more

Wednesday, January 5, 2011

Rituximab Biosimilar to Be Developed by Spectrum and Viropro

Wednesday, January 5, 2011
0 comments

Genetic Engineering & Biotechnology News
Quick Links
  Visit GEN on Twitter
 
GEN NEWS HIGHLIGHTS
Wednesday, January 5, 2011


Rituximab Biosimilar to Be Developed by Spectrum and Viropro
Roche/Genentech's mAb therapeutic raked in $5.6 billion in 2009 sales, and patents start expiring in 2014.

Beckman Coulter to Develop aNK Assay for Pivotal Trial of Transgene's NSCLC Drug
French company projects that Phase IIb/III study with TG4010 will start later this year.

DBV Raises $25.5M in Series C for Clinical-Stage Food Allergy Desensitization Technology
DBV's Viaskin platform is already undergoing human testing in patients with peanut and milk allergies.


Advertisement

SPONSORED LINK
Make your Biomanufacturing voice heard! Support effective industry growth & planning. 8th Annual Biomanufacturing study benchmarks critical global trends: Budget, new technologies, capacity, outsourcing hiring, downstream, disposables, expression systems, cost cutting, quality, more. BioPlan Associates, Inc.
FREE summary, plus donation to GAVI, or ACS
Click Here! Receive FREE summary


Merck KGaA Buys Chinese Cell Culture Media Firm Beijing Skywing for About $18.8M
It is hoped that the new client base in China will provide promising opportunities for Merck Millipore.

Omeros Gains Rights to Antifibrinolytic Agents
Candidates were licensed from The Regents of the University of California.

Thomson Reuters and ChemAxon Couple Offerings to Search and Visualize Chemical Patents
Users can now research Markush structures using ChemAxon's JChem software platform.

Cephalon to Evaluate ImmunGene's mAb-Cytokine Fusion Technology for Six Cancer Targets
ImmunGene claims this platform efficiently targets cancer cells and reduces cytokine toxicity.

Lilly to Use ArGEN-X Technology for mAb R&D
The Simple Antibody platform will be utilized, and Lilly will supply targets.

Lonza to Leverage IDBS' Data Management and Execution Solution
Bioprocess Execution System will allow storing of data in context and more efficient sharing between groups.

AstraZeneca Turns to Kinaxo to Study PTMs Related to an Oncology Program
Kinaxo's Cellular Target Profiling technology combines mass spec and software capabilities.

Almirall and Forest Project Mid-2011 Aclidinium Filing as Third Phase III COPD Trial Triumphs
Firms also anticipate starting Phase III combination-therapy studies during second half of 2011.


You can view more news broken down into over 90 categories and updated daily.



Analysis & Insight
Analysis & Insight 2010 in Review: Biotechnology Highlights
Gene patenting and ESCs were back in the headlines along with breakthroughs in sequencing, syn bio, and other fields.     More A&Is

Webinars
Available on Demand. Original Broadcast Date - December 16, 2010
Simplifying Targeted Protein Quantification with Mass Spec: The SRM Atlas and Multiplexed MRM Protein Assays
Sponsored by: Agilent Technologies

In Case You Missed It:
If you couldn't attend a previous webinar, be sure to check out our On-Demand Archives.


Application Note Library
More App Notes

Online Exclusives
BLOGBIOTECH:
Will FDA Bid Adieu to Auld Lang Syne and Open Up to New Drugs and Devices    More Blogs



More at GEN
GEN Subscriber Tools



Subscription Center l Unsubscribe l Update Your Profile l About GEN

IMPORTANT! Make sure you receive your chosen GEN e-Newsletters. Add update@genengnews.com to your Address Book or Safe Senders List. It's easy! Click HERE for instructions.

Contact Us For:
Advertising   Editorial   Business and Partnership Opportunities


This email was sent by:
Genetic Engineering & Biotechnology News
140 Huguenot St.,
New Rochelle, NY 10801, USA
 

read more

Monday, January 3, 2011

Scholarship World Wide

Monday, January 3, 2011
0 comments

Basic Stipendien - What You Free College Geld wissen sollten
Artikel zur Verfügung gestellt von bioindo.blogspot.com

Einige Schüler und Eltern, die "Wissenschaft" sind andere als die verworrenen Hochschule: Studenten Darlehen, FAFSA, Nachhilfe, EFC, Stipendien, Arbeit zu studieren. Sie sind noch nicht in der Lage, mehr über das Prozess-Know-Stipendium, Tausende von Dollar sparen versuchen, die Kosten der Bildung zu decken.

Was ist das Stipendium?
Die Stipendien werden in verschiedenen Formen angeboten, aber sie sind in der Regel "geschenktes Geld" für das College. Anders als Darlehen, Stipendien wollen nicht den Stipendiengeber zahlen. Einige Stipendien werden an Studenten in Form von direkten Kontrolle vergeben, während andere Stipendien an der Heimatuniversität oder Fachhochschule geschrieben werden. Mehrere Arten von Anbietern Thema Stipendien: Vereine und Organisationen, Stiftungen, Unternehmen, Schulen, Universitäten, Regierungsbehörden und andere.

Wer kann Stipendien?
Dies ist ein verbreiteter Irrtum, dass Stipendien nur zu "korrigieren-A" Student. In der Tat, es gibt alle Arten von Stipendien für alle Studierenden, einschließlich derjenigen, die weniger als perfekte Zeugnisse sind. Einige Stipendien sind für Athleten, schrieb einige der Schüler in bestimmten Bereichen, und andere für Zivildiener. Einige Anbieter Stipendium möchte nur, um Studenten für das Leben in der Stadt oder des Landes Belohnung! Auch Studenten glauben irrtümlich, dass nur die obligatorischen Abiturienten College-Stipendien beantragen. Die Stipendien sind für Studenten verfügbar auf allen Ebenen im ersten Jahr Undergraduate-und Postgraduate Doktoranden. Es gibt auch Zuschüsse eine nicht-traditionelle Lerner, und umgekehrt.

So finden Sie Stipendien für Studenten?
Finden Stipendien kann ein langer Prozess, aber nicht, wenn die Studierenden die Forschungsförderung von zuverlässigen und präzisen Service im Internet, wie ScholarshipExperts.com. Die Schüler können auch beantragen, dass die örtliche Schule beratend Leitlinien oder kommen für nationale Preise. Die Schüler sollten an College finanzielle Hilfe Büro oder Universität sie teilnehmen möchten, wenn sie kommen für Stipendien von der Schule angeboten werden.

Wenn die Schüler sehen für Stipendien?
Jede Anwendung hat ihre eigenen Fristen. Es gibt Tausende von Stipendienprogrammen in den Frühling und Sommer Termine und mehr Zeit im Herbst und Winter. Der Schlüssel ist, nie aufhören Suche nach neuen Stipendium führt, auch in der anfänglichen ersten Jahr am College. Eine gute Faustregel ist es, auf der Suche nach Stipendien während der akademischen Laufbahn.

read more

Sunday, July 6, 2008

APOPTOSIS------How is our cells dead ???

Sunday, July 6, 2008
1 comments

This video will give you an inspiration, how our cell will die...Nice creation of the God....!!!



Apoptosis

For every cell, there is a time to live and a time to die.

There are two ways in which cells die:

* They are killed by injurious agents.
* They are induced to commit suicide.

Death by injury
Cells that are damaged by injury, such as by

* mechanical damage
* exposure to toxic chemicals

undergo a characteristic series of changes:

* They (and their organelles like mitochondria) swell (because the ability of the plasma membrane to control the passage of ions and water is disrupted).
* The cell contents leak out, leading to
* inflammation of surrounding tissues.

Death by suicide
Cells that are induced to commit suicide:

* shrink;
* develop bubble-like blebs on their surface;
* have the chromatin (DNA and protein) in their nucleus degraded;
* have their mitochondria break down with the release of cytochrome c;
* break into small, membrane-wrapped, fragments.
* The phospholipid phosphatidylserine, which is normally hidden within the plasma membrane, is exposed on the surface.
* This "eat me" signal is bound by receptors on phagocytic cells like macrophages and dendritic cells which then engulf the cell fragments.
* The phagocytic cells secrete cytokines that inhibit inflammation (e.g., IL-10 and TGF-β)

The pattern of events in death by suicide is so orderly that the process is often called programmed cell death or PCD. The cellular machinery of programmed cell death turns out to be as intrinsic to the cell as, say, mitosis.

Programmed cell death is also called apoptosis. (There is no consensus yet on how to pronounce it; some say APE oh TOE sis; some say uh POP tuh sis.)
Why should a cell commit suicide?
There are two different reasons.
1. Programmed cell death is as needed for proper development as mitosis is.
Examples:

* The resorption of the tadpole tail at the time of its metamorphosis into a frog occurs by apoptosis.
* The formation of the fingers and toes of the fetus requires the removal, by apoptosis, of the tissue between them.
* The sloughing off of the inner lining of the uterus (the endometrium) at the start of menstruation occurs by apoptosis.
* The formation of the proper connections (synapses) between neurons in the brain requires that surplus cells be eliminated by apoptosis

2. Programmed cell death is needed to destroy cells that represent a threat to the integrity of the organism.
Examples:

Cells infected with viruses
One of the methods by which cytotoxic T lymphocytes (CTLs) kill virus-infected cells is by inducing apoptosis [diagram of the mechanism]. (And some viruses mount countermeasures to thwart it — Link)

Cells of the immune system
As cell-mediated immune responses wane, the effector cells must be removed to prevent them from attacking body constituents. CTLs induce apoptosis in each other and even in themselves. Defects in the apoptotic machinery is associated with autoimmune diseases such as lupus erythematosus and rheumatoid arthritis.

Cells with DNA damage
Damage to its genome can cause a cell

* to disrupt proper embryonic development leading to birth defects
* to become cancerous.

Cells respond to DNA damage by increasing their production of p53. p53 is a potent inducer of apoptosis. Is it any wonder that mutations in the p53 gene, producing a defective protein, are so often found in cancer cells (that represent a lethal threat to the organism if permitted to live)?

Cancer cells
Radiation and chemicals used in cancer therapy induce apoptosis in some types of cancer cells.

What makes a cell decide to commit suicide?
The balance between:

* the withdrawal of positive signals; that is, signals needed for continued survival, and
* the receipt of negative signals.

Withdrawal of positive signals
The continued survival of most cells requires that they receive continuous stimulation from other cells and, for many, continued adhesion to the surface on which they are growing. Some examples of positive signals:

* growth factors for neurons
* Interleukin-2 (IL-2), an essential factor for the mitosis of lymphocytes

Receipt of negative signals

* increased levels of oxidants within the cell
* damage to DNA by these oxidants or other agents like
o ultraviolet light
o x-rays
o chemotherapeutic drugs
* accumulation of proteins that failed to fold properly into their proper tertiary structure
* molecules that bind to specific receptors on the cell surface and signal the cell to begin the apoptosis program. These death activators include:
o Tumor necrosis factor-alpha (TNF-α ) that binds to the TNF receptor;
o Lymphotoxin (also known as TNF-β ) that also binds to the TNF receptor;
o Fas ligand (FasL), a molecule that binds to a cell-surface receptor named Fas (also called CD95).

The Mechanisms of Apoptosis
There are 3 different mechanisms by which a cell commits suicide by apoptosis.

1. One generated by signals arising within the cell;
2. another triggered by death activators binding to receptors at the cell surface:
* TNF-α
* Lymphotoxin
* Fas ligand (FasL)
3. A third that may be triggered by dangerous reactive oxygen species.

1. Apoptosis triggered by internal signals: the intrinsic or mitochondrial pathway

* In a healthy cell, the outer membranes of its mitochondria display the protein Bcl-2 on their surface. Bcl-2 inhibits apoptosis.
* Internal damage to the cell (e.g., from reactive oxygen species) causes
o related proteins, Bad and Bax, to migrate to the surface of the mitochondrion where they bind to Bcl-2 — blocking its protective effect — and punch holes in the outer mitochondrial membrane, causing
o cytochrome c to leak out.
* The released cytochrome c binds to the protein Apaf-1 ("apoptotic protease activating factor-1").
* Using the energy provided by ATP,
* these complexes aggregate to form apoptosomes.
* The apoptosomes bind to and activate caspase-9.
* Caspase-9 is one of a family of over a dozen caspases. They are all proteases. They get their name because they cleave proteins — mostly each other — at aspartic acid (Asp) residues).
* Caspase-9 cleaves and, in so doing, activates other caspases (caspase-3 and -7).
* The activation of these "executioner" caspases creates an expanding cascade of proteolytic activity (rather like that in blood clotting and complement activation) which leads to
o digestion of structural proteins in the cytoplasm,
o degradation of chromosomal DNA, and
* phagocytosis of the cell.

2. Apoptosis triggered by external signals: the extrinsic or death receptor pathway

* Fas and the TNF receptor are integral membrane proteins with their receptor domains exposed at the surface of the cell
* binding of the complementary death activator (FasL and TNF respectively) transmits a signal to the cytoplasm that leads to
* activation of caspase 8
* caspase 8 (like caspase 9) initiates a cascade of caspase activation leading to
* phagocytosis of the cell.

Example (right): When cytotoxic T cells recognize (bind to) their target,

* they produce more FasL at their surface.
* This binds with the Fas on the surface of the target cell leading to its death by apoptosis.

The early steps in apoptosis are reversible — at least in C. elegans. In some cases, final destruction of the cell is guaranteed only with its engulfment by a phagocyte.
3. Apoptosis-Inducing Factor (AIF)

Neurons, and perhaps other cells, have another way to self-destruct that — unlike the two paths described above — does not use caspases.
Apoptosis-inducing factor (AIF) is a protein that is normally located in the intermembrane space of mitochondria. When the cell receives a signal telling it that it is time to die, AIF

* is released from the mitochondria (like the release of cytochrome c in the first pathway);
* migrates into the nucleus;
* binds to DNA, which
* triggers the destruction of the DNA and cell death.

Apoptosis and Cancer
Some viruses associated with cancers use tricks to prevent apoptosis of the cells they have transformed.

* Several human papilloma viruses (HPV) have been implicated in causing cervical cancer. One of them produces a protein (E6) that binds and inactivates the apoptosis promoter p53.
* Epstein-Barr Virus (EBV), the cause of mononucleosis and associated with some lymphomas
o produces a protein similar to Bcl-2
o produces another protein that causes the cell to increase its own production of Bcl-2. Both these actions make the cell more resistant to apoptosis (thus enabling a cancer cell to continue to proliferate).

Even cancer cells produced without the participation of viruses may have tricks to avoid apoptosis.

* Some B-cell leukemias and lymphomas express high levels of Bcl-2, thus blocking apoptotic signals they may receive. The high levels result from a translocation of the BCL-2 gene into an enhancer region for antibody production. [Discussion].
* Melanoma (the most dangerous type of skin cancer) cells avoid apoptosis by inhibiting the expression of the gene encoding Apaf-1.
* Some cancer cells, especially lung and colon cancer cells, secrete elevated levels of a soluble "decoy" molecule that binds to FasL, plugging it up so it cannot bind Fas. Thus, cytotoxic T cells (CTL) cannot kill the cancer cells by the mechanism shown above.
* Other cancer cells express high levels of FasL, and can kill any cytotoxic T cells (CTL) that try to kill them because CTL also express Fas (but are protected from their own FasL).

Apoptosis in the Immune System

The immune response to a foreign invader involves the proliferation of lymphocytes — T and/or B cells [Link]. When their job is done, they must be removed leaving only a small population of memory cells [Link]. This is done by apoptosis.

Very rarely humans are encountered with genetic defects in apoptosis. The most common one is a mutation in the gene for Fas, but mutations in the gene for FasL or even one of the caspases are occasionally seen. In all cases, the genetic problem produces autoimmune lymphoproliferative syndrome or ALPS.
Features:

* an accumulation of lymphocytes in the lymph nodes and spleen greatly enlarging them.
* the appearance of clones that are autoreactive; that is, attack "self" components producing such autoimmune disorders as
o hemolytic anemia
o thrombocytopenia
* the appearance of lymphoma — a cancerous clone of lymphocytes.

In most patients with ALPS, the mutation is present in the germline; that is, every cell in their body carries it. In a few cases, however, the mutation is somatic; that is, has occurred in a precursor cell in the bone marrow. These later patients are genetic mosaics — with some lymphocytes that undergo apoptosis normally and others that do not. The latter tend to out-compete the former and grow to become the major population in the lymph nodes and blood.
Apoptosis and AIDS

The hallmark of AIDS (acquired immunodeficiency syndrome) is the decline in the number of the patient's CD4+ T cells (normally about 1000 per microliter (µl) of blood). CD4+ T cells are responsible, directly or indirectly (as helper cells), for all immune responses. When their number declines below about 200 per µl, the patient is no longer able to mount effective immune responses and begins to suffer a series of dangerous infections.

What causes the disappearance of CD4+ T cells?
HIV (human immunodeficiency virus) invades CD4+ T cells, and one might assume that it this infection by HIV that causes the great dying-off of these cells. However, that appears not to the main culprit. Fewer than 1 in 100,000 CD4+ T cells in the blood of AIDS patients are actually infected with the virus.

So what kills so many uninfected CD4+ cells?

The answer is clear: apoptosis.
The mechanism is not clear. There are several possibilities. One of them:

* All T cells, both infected and uninfected, express Fas.
* Expression of a HIV gene (called Nef) in a HIV-infected cell causes
o the cell to express high levels of FasL at its surface
o while preventing an interaction with its own Fas from causing it to self-destruct.
* However, when the infected T cell encounters an uninfected one (e.g. in a lymph node), the interaction of FasL with Fas on the uninfected cell kills it by apoptosis.

Apoptosis and Organ Transplants
For many years it has been known that certain parts of the body such as

* the anterior chamber of the eye
* the testes

are "immunologically privileged sites". Antigens within these sites fail to elicit an immune response.

It turns out that cells in these sites differ from the other cells of the body in that they express high levels of FasL at all times. Thus antigen-reactive T cells, which express Fas, would be killed when they enter these sites. (This is the reverse of the mechanism described above.)
This finding raises the possibility of a new way of preventing graft rejection.

If at least some of the cells on a transplanted kidney, liver, heart, etc. could be made to express high levels of FasL, that might protect the graft from attack by the T cells of the host's cell-mediated immune system. If so, then the present need for treatment with immunosuppressive drugs for the rest of the transplant recipient's life would be reduced or eliminated.

So far, the results in animal experiments have been mixed. Allografts engineered to express FasL have shown increased survival for kidneys but not for hearts or islets of Langerhans.
Apoptosis in Plants

Plant, too, can turn on a system of programmed cell death; for example, in an attempt to halt the spread of virus infection.

The mechanism differs from that in animals although it, too, involves a protease that — like caspases — cleaves other proteins at Asp (and Asn) residues.

Activation of this enzyme destroys the central vacuole, which is followed by disintegration of the rest of the cell.

read more
 

Popular Posts